Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Stoke Therapeutics (STOK)

September 11, 2024 6:38 AM EDT Send to a Friend
H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Buy rating and $35.00 price target on Stoke Therapeutics (NASDAQ: STOK).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login